What You Should Know
- The Acquisition: Health Recovery Solutions (HRS), a dominant player in remote patient monitoring (RPM) and enterprise remote care, has officially acquired Rimidi, an Atlanta-based chronic disease management company. Financial details were not disclosed.
- The Strategic Shift: The deal accelerates HRS’s transition from a primarily post-acute monitoring company into a comprehensive, end-to-end longitudinal care provider. It bolsters the “PatientFirst Pathways” care model HRS introduced in 2025.
- The Clinical Payload: Rimidi brings deep expertise in the ambulatory setting, specifically targeting diabetes and cardiometabolic management. This includes advanced integration capabilities with major Continuous Glucose Monitoring (CGM) devices like Dexcom, FreeStyle Libre, and Eversense directly into the EHR workflow.
- The Leadership Move: As part of the acquisition, Rimidi’s CEO and Founder, Dr. Lucienne Ide, will step into the role of Chief Medical Officer for HRS, signaling a heavy emphasis on clinical rigor and outcomes over pure software deployment.
- The ROI Focus: Rimidi’s platform has a proven track record of reducing the total cost of care, with one healthcare partner achieving an average 2.8% reduction in hemoglobin A1c levels and driving meaningful reductions in hospitalizations for high-risk type 2 diabetes patients.
Merging the Post-Acute with the Ambulatory
HRS has spent over a decade dominating the post-acute and hospital-at-home sectors. With over one million patients monitored to date, their infrastructure is built to handle complex operational logistics and high-acuity interventions.
Rimidi, on the other hand, was built by doctors, for doctors, to thrive in the ambulatory (outpatient) setting. The platform excels at ingesting continuous clinical data and transforming it into actionable insights for primary and specialty care clinics. By bolting Rimidi onto its existing architecture, HRS is bridging the gap between acute recovery and everyday life.
“HRS’s leadership in enterprise remote patient care and dedication to quality perfectly complement the mission Rimidi was founded on. By integrating Rimidi’s extensive experience and capabilities in ambulatory disease management into their comprehensive platform, we can jointly support the entire patient journey across care settings, clinical conditions, and levels of patient acuity. Our combined solutions will enhance the reach and effectiveness of HRS’s already high‑value offerings, amplifying the positive impact we can make on patient outcomes,” noted Dr. Lucienne Ide, CEO and Founder of Rimidi, who will now serve as Chief Medical Officer for HRS.
The Continuous Glucose Monitoring (CGM) Catalyst
One of the most valuable assets HRS acquires in this deal is Rimidi’s sophisticated integration with Continuous Glucose Monitors (CGMs). Driven by expanding insurance coverage, the CGM market is exploding. However, simply handing a patient a Dexcom or a FreeStyle Libre does not improve care if the resulting data is not actionable for the physician. Rimidi aggregates massive streams of data from leading CGM devices and pipes those glucose insights directly into the clinician’s existing Electronic Health Record (EHR) workflow. The integration of Rimidi’s specialized diabetes management capability with HRS’s robust operational scale will enable health systems to standardize how they monitor their costliest chronic populations.
“HRS is committed to expanding enterprise remote patient care to meet evolving customer needs,” said Jason Comer, CEO of HRS. “With our recent introduction of PatientFirst Pathways and expansion into Chronic Care Management, this acquisition enhances our ability to deliver comprehensive longitudinal care. Rimidi’s clinical workflow expertise, deep roots in diabetes management, and strong track record of improving patient outcomes make them an ideal addition.”
